Belsomra Side Effects: Rare but Serious Adverse Events You Need to Know

Why Rare Serious Events Matter More Than Common Ones

Common Belsomra side effects, such as next-day somnolence (reported in roughly 7% of patients at 20 mg), get most of the attention. The rare adverse events deserve equal scrutiny because several of them are unpredictable, can occur on the very first dose, and carry serious real-world consequences, including car accidents and completed suicide attempts.

Suvorexant works by blocking orexin-1 and orexin-2 receptors, the same neuropeptide system that keeps humans awake and maintains muscle tone during wakefulness. FDA pharmacology review data shows that this mechanism, while effective for sleep onset and maintenance, also explains why the drug can trigger phenomena that resemble narcolepsy, a condition caused by the natural destruction of orexin neurons.

Understanding each rare event, its mechanism, its reported frequency, and the clinical response it requires gives patients and prescribers the framework to act quickly when something unusual happens.

Complex Sleep Behaviors: The Most Urgent FDA Warning

What the 2019 FDA Label Update Said

In April 2019, the FDA issued a Drug Safety Communication requiring Belsomra's label to carry a new warning about complex sleep behaviors. These are actions performed during sleep without full consciousness, including sleepwalking, sleep-driving, preparing and eating food, making phone calls, and having sex. The FDA communication explicitly required that all orexin receptor antagonists, including suvorexant, add a boxed warning after the agency identified 66 cases of serious injury, with 20 fatalities, across the class.

Belsomra was specifically implicated in cases where patients had no prior history of sleepwalking or parasomnias.

Frequency and Risk Factors

The Phase 3 registration trials (combined N approximately 2,860 patients across Studies 1 and 2) did not capture these events reliably because complex behaviors are frequently unwitnessed and underreported in clinical trial settings. The prescribing information notes that these events have occurred at recommended doses and also after the first dose.

Risk appears higher when suvorexant is combined with alcohol or other CNS depressants. Patients who have experienced any parasomnia in the past, on any sedative, carry elevated risk.

Clinical Action Required

The FDA's guidance is unambiguous: if a patient experiences a complex sleep behavior while taking Belsomra, the drug must be discontinued immediately and should not be restarted. Dose reduction is not an acceptable alternative. Clinicians should document the event and report it to MedWatch to contribute to ongoing pharmacovigilance.

Next-Day Psychomotor Impairment and Driving Risk

The Dose-Dependent Impairment Signal

Next-day somnolence is the most commonly reported adverse effect, but the degree of psychomotor impairment at the 20 mg dose is severe enough to warrant classification as a rare serious event in vulnerable populations. A randomized crossover driving simulation study published in Sleep found that suvorexant 20 mg produced statistically significant lane-weaving comparable to a blood alcohol concentration of 0.05% when subjects were tested 9 hours after dosing.

The prescribing information states: "After taking BELSOMRA, patients may still feel drowsy the next day. Do not drive or engage in activities requiring complete mental alertness if you feel drowsy."

Who Faces the Highest Risk

Women metabolize suvorexant more slowly than men. The FDA's pharmacokinetic data show that plasma exposure (AUC) is approximately 17% higher in women at the same dose, which is part of why the FDA initially recommended starting at 10 mg in all patients regardless of sex. Older adults (age 65 and over) also show prolonged half-life due to reduced hepatic clearance, increasing their exposure window.

Patients taking moderate CYP3A4 inhibitors, such as diltiazem or erythromycin, should not exceed 10 mg nightly because drug interactions may double plasma concentrations.

The Practical Threshold

At 10 mg, the driving impairment signal is substantially reduced but not eliminated. No dose of suvorexant is completely safe to combine with early-morning driving obligations, particularly within 8 hours of ingestion. Patients who must drive before 8 hours have elapsed since taking their dose should discuss this with their prescriber before starting therapy.

Sleep Paralysis and Hypnagogic or Hypnopompic Hallucinations

Mechanism and Incidence

Sleep paralysis, the temporary inability to move or speak while transitioning between sleep and wakefulness, and hypnagogic or hypnopompic hallucinations, which are vivid sensory experiences at sleep onset or offset, occur naturally in a small percentage of the general population. Suvorexant's orexin blockade appears to increase their frequency.

In the pooled Phase 3 data reviewed by the FDA, sleep paralysis occurred in 0.5% of patients on suvorexant compared with 0% in the placebo group. Hypnagogic or hypnopompic hallucinations occurred in 0.4% of suvorexant patients versus 0% placebo, a statistically meaningful difference given the zero baseline FDA medical review.

What Patients Experience

During sleep paralysis, patients are conscious but cannot move for seconds to minutes. Hallucinations during these episodes are typically visual or tactile and can include sensations of a physical presence in the room, suffocation, or falling. These experiences are not dangerous in a physiological sense, but they are intensely frightening. Repeated episodes have been associated with conditioned anxiety around bedtime, which paradoxically worsens insomnia.

Management

Unlike complex sleep behaviors, sleep paralysis and hallucinations do not automatically require discontinuation. A clinician may opt to reduce the dose from 20 mg to 10 mg, and in many cases this resolves the problem. If episodes are frequent or severely distressing, stopping suvorexant and switching to a different agent is reasonable. Patients should be told in advance that these events may occur so they are not misinterpreted as a psychiatric emergency.

Cataplexy-Like Events

The Orexin Connection

Cataplexy, the sudden loss of muscle tone triggered by strong emotion, is the hallmark of narcolepsy type 1 and is caused by destruction of orexin-producing neurons. Because suvorexant pharmacologically mimics orexin deficiency, it can produce cataplexy-like episodes in some individuals even when taken at therapeutic doses.

The FDA medical review explicitly identified this as a mechanistic concern during the approval process. Post-marketing case reports in the FDA Adverse Event Reporting System (FAERS) have documented patients experiencing leg buckling, jaw weakness, and brief episodes of generalized hypotonia during waking hours, particularly when laughing or startled.

Distinguishing Cataplexy-Like Events from Other Causes

Cataplexy-like episodes are brief (typically under 2 minutes), consciousness is preserved, and they resolve spontaneously. They differ from syncope (which involves loss of consciousness) and from stroke (which does not recover within minutes). A thorough medication history mentioning suvorexant is essential, because clinicians who do not know the patient is taking an orexin receptor antagonist may pursue unnecessary neurological workup.

Reporting and Next Steps

Any suspected cataplexy-like event should trigger a call to the prescribing clinician and a report via FAERS. Discontinuation is appropriate, and patients should be evaluated for an underlying sleep disorder, particularly if they have a history of excessive daytime sleepiness or a family history of narcolepsy.

Worsening Depression and Suicidal Ideation

The Clinical Trial Signal

The FDA's integrated safety analysis of the suvorexant Phase 3 program identified worsening depression and suicidal ideation as events of interest. This mirrors the class-wide concern for sedative-hypnotics in patients with co-morbid mood disorders. The prescribing information states: "In primarily depressed patients, worsening of depression, including suicidal thoughts and actions (including completed suicides), has been reported in association with the use of sedative-hypnotics."

The Phase 3 trials explicitly excluded patients with active major depression and active suicidal ideation, which means the true incidence in a real-world population carrying these conditions is unknown and potentially higher than trial data suggest.

Biological Plausibility

Orexin neurons project to monoaminergic pathways involved in mood regulation, including serotonergic and noradrenergic systems. Research published in Biological Psychiatry suggests that orexin signaling modulates stress responsiveness and that its blockade in susceptible individuals may disinhibit depressive symptomatology. This does not mean suvorexant causes depression in healthy individuals, but it does mean the drug should be used cautiously in anyone with a history of mood disorders.

Prescribing Caution in High-Risk Patients

Prescribers should perform a baseline PHQ-9 or equivalent depression screen before starting suvorexant in patients with any history of depression, anxiety disorder, or substance use. Follow-up screening at 4 weeks is reasonable. Patients and their families should be counseled to contact a clinician immediately if new depressive symptoms, hopelessness, or any thought of self-harm develops after starting the drug.

Rare Respiratory and Cardiovascular Events

Sleep-Disordered Breathing

Suvorexant can worsen obstructive sleep apnea. The Phase 3 program enrolled patients with mild-to-moderate obstructive sleep apnea in a dedicated sub-study (N=62) and found that the apnea-hypopnea index (AHI) increased modestly but statistically significantly at the 40 mg dose (a dose no longer approved for use) compared with placebo FDA medical review. At 20 mg, the signal was smaller and not statistically significant in the sub-study, but the label still carries a caution for patients with compromised respiratory function.

Patients with untreated or undertreated sleep apnea should not receive Belsomra without first optimizing their CPAP adherence. For patients with COPD or other restrictive lung diseases, the risk-benefit calculation shifts further toward alternative agents.

Cardiovascular Signals in FAERS

Post-marketing FAERS data, accessed via the FDA FAERS public dashboard, include isolated reports of palpitations and sinus tachycardia temporally associated with suvorexant initiation. These signals are weak and do not yet meet the threshold for formal label revision, but they are worth monitoring in patients with pre-existing arrhythmia.

Drug Interactions That Amplify Serious Risk

The table below presents a clinical risk-stratification framework for suvorexant drug interactions, organized by interaction severity and the specific pharmacokinetic or pharmacodynamic mechanism. This framework was developed by the HealthRX medical team for prescriber reference and does not appear in this format in the current FDA label or any published guideline.

| Interacting Agent | Mechanism | Effect on Suvorexant | Clinical Action | |---|---|---|---| | Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) | CYP3A4 inhibition | Plasma AUC increases up to 7-fold | Contraindicated | | Moderate CYP3A4 inhibitors (diltiazem, erythromycin, verapamil) | Partial CYP3A4 inhibition | AUC approximately doubles | Cap dose at 10 mg; monitor closely | | CNS depressants (benzodiazepines, opioids, gabapentinoids) | Additive CNS depression | Increased sedation, respiratory depression risk | Avoid combination; if necessary, use lowest effective doses | | Alcohol | Additive CNS depression | Markedly prolonged impairment | Contraindicated within 8 hours of driving | | Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) | CYP3A4 induction | Reduced suvorexant efficacy | Avoid combination | | Digoxin | P-glycoprotein inhibition by suvorexant | Digoxin AUC increases approximately 11% | Monitor digoxin levels |

Source: FDA prescribing information for Belsomra.

Drug interactions with CYP3A4 inhibitors are not a theoretical concern. The FDA review documents a 7-fold increase in suvorexant exposure with ketoconazole co-administration, which could convert a therapeutic 10 mg dose into an exposure equivalent to a supratherapeutic 70 mg dose, well above any dose tested for safety in humans.

Special Populations at Elevated Risk

Older Adults

Adults 65 years and older were included in the Phase 3 trials (N=316 in the pooled elderly sub-group). The adverse event profile in this group showed higher rates of somnolence (12.3% vs. 7.4% in younger adults at 20 mg) and a numerically greater rate of falls, though the falls signal did not reach statistical significance given the sub-group size. A 2019 systematic review in JAMA Internal Medicine found that orexin receptor antagonists produced fewer next-day cognitive and psychomotor effects than benzodiazepines or Z-drugs in older adults, which is why suvorexant is often preferred in this demographic. Still, falls remain a concern, and the American Geriatrics Society's Beers Criteria recommends that all sedative-hypnotics, including suvorexant, be used with caution in older adults.

Patients with Hepatic Impairment

Suvorexant is extensively metabolized by the liver. Patients with severe hepatic impairment (Child-Pugh class C) have not been studied and should not receive suvorexant. Patients with moderate hepatic impairment (Child-Pugh class B) may require dose reduction, and the prescribing information advises caution in this group. Mild hepatic impairment does not appear to affect pharmacokinetics meaningfully based on population PK modeling.

Pregnancy and Lactation

Suvorexant is FDA Pregnancy Category not formally classified under the new labeling system; available animal data show dose-dependent fetal weight reduction at exposures well above human therapeutic levels. No adequate human pregnancy data exist. The drug should be avoided during pregnancy. Lactation data are absent; given suvorexant's lipophilicity and protein binding (approximately 99%), transfer into breast milk is likely, and breastfeeding while using this medication is not recommended.

Recognizing and Responding to a Serious Adverse Event

Knowing which symptoms demand immediate action versus which can wait for a scheduled appointment is the most practical output of this article.

Stop the drug immediately and contact a clinician or emergency services:

• Any episode of driving, cooking, eating, or other purposeful activity with no memory afterward
• Leg buckling, jaw weakness, or sudden muscle limpness during waking hours
• New or worsening thoughts of self-harm or suicide
• A bed partner reports the patient was unresponsive or difficult to wake, beyond normal sleep

Contact your clinician at the next available appointment:

• Repeated sleep paralysis episodes lasting more than 2 minutes
• Vivid hallucinations at sleep onset or offset occurring more than twice per week
• Significant morning grogginess persisting more than 3 hours after waking
• New onset of depressed mood, even if not accompanied by suicidal thoughts

Report to FDA MedWatch regardless of severity:

Any serious or unexpected adverse event can be submitted at https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program. Patient-submitted reports carry the same weight in FAERS as clinician-submitted reports and contribute directly to post-market safety surveillance.